Rapid Analysis of Pharmacology for Infectious Diseases by Hopkins, Andrew L et al.
1292  Current Topics in Medicinal Chemistry, 2011, 11, 1292-1300
   1568-0266/11 $58.00+.00  © 2011 Bentham Science Publishers Ltd.
Rapid Analysis of Pharmacology for Infectious Diseases 
Andrew L. Hopkins
1,*, G. Richard Bickerton
1, Ian M. Carruthers
1, Stephen K. Boyer
2,  
Harvey Rubin
3 and John P. Overington
4
1Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dow Street, 
Dundee, DD1 5EH, UK; 
2IBM, Almaden Research Center, 650 Harry Road, San Jose, California 95120-6099, USA; 
3Departments of Medicine, Microbiology and Computer Science, and the University of Pennsylvania Institute for   
Strategic Threat Analysis and Response, University of Pennsylvania, 522 Johnson Pavilion, Philadelphia, PA 19104, 
USA; 
4EMBL, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom, CB10 
1SD, UK 
Abstract: Pandemic, epidemic and endemic infectious diseases are united by a common problem: how do we rapidly and 
cost-effectively identify potential pharmacological interventions to treat infections? Given the large number of emerging 
and neglected infectious diseases and the fact that they disproportionately afflict the poorest members of the global soci-
ety, new ways of thinking are required to develop high productivity discovery systems that can be applied to a large num-
ber of pathogens. The growing availability of parasite genome data provides the basis for developing methods to priori-
tize, a priori potential drug targets and analyze the pharmacological landscape of an infectious disease. Thus the overall 
objective of infectious disease informatics is to enable the rapid generation of plausible, novel medical hypotheses of test-
able pharmacological experiments, by uncovering undiscovered relationships in the wealth of biomedical literature and 
databases that were collected for other purposes. In particular our goal is to identify potential drug targets present in a 
pathogen genome and prioritize which pharmacological experiments are most likely to discover drug-like lead compounds 
rapidly against a pathogen (i.e. which specific compounds and drug targets should be screened, in which assays and where 
they can be sourced). An integral part of the challenge is the development and integration of methods to predict druggabil-
ity, essentiality, synthetic lethality and polypharmocology in pathogen genomes, while simultaneously integrating the in-
evitable issues of chemical tractability and the potential for acquired drug resistance from the start. 
Keywords: Chemogenomics, target identification, druggable genome. 
1. INTRODUCTION 
  The World Health Organisation estimates that one in six 
of the world’s population suffers from one or more neglected 
infectious diseases such as onchocerciasis, trypanosomiasis, 
lymphatic filariasis, schistosomiasis, soil-transmitted helmin-
thiasis, and blinding trachoma. These are the same poor 
populations that are at risk from the major infectious disease 
burdens of malaria, tuberculosis and human immunodefi-
ciency virus [1]. Deaths from infectious diseases occur dis-
proportionately in the developing world, where they are the 
biggest killer of children and young adults. Communicable 
diseases account for 50% of the disease burden of the devel-
oping countries, which represent 4.8 billion people, 80% of 
the world population. Yet despite this disease burden only 
thirteen new drugs were approved between 1975 and 1999 
for the tropical diseases [2]. The developed world cannot be 
complacent about infectious diseases within its own borders. 
Only one new class of antibiotics for gram-positive bacteria, 
the oxazolidinones, has been approved in the past four dec-
ades [3]. The prospect of new antibiotics against gram-
negative bacteria is even bleaker with few drugs against this 
class of pathogen currently in clinical development [4]. 
Globally, nearly 340 infectious diseases are reported to 
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have emerged between 1940 and 2004, including many drug-
resistant strains of pathogens [5]. The emerging infectious 
diseases also present a danger to the health and security of 
the populations of the OECD countries, whether it is the rise 
of drug resistant pathogens, the threat of a global pandemic 
or the possibility of a bioterrorist attack. 
  Infectious diseases pose different threats to different con-
stituencies and thus are often treated as separate problems by 
governments, businesses, philanthropies and research fun-
ders: neglected diseases are treated as global health prob-
lems; emerging and pandemic diseases as public health is-
sues; and bio-defence as a national security issue. However, 
all of these diseases are united by a common problem: how 
do we rapidly and cost-effectively identify potential pharma-
cological interventions to treat infections? Given the large 
number of emerging and neglected infectious diseases and 
the fact that they often affect the poorest members of society, 
a general system is required that can be flexibly applied to a 
larger number of diverse organisms. Compounding the prob-
lem of research for new drugs for neglected and emerging 
infectious diseases is the current productivity paradox in the 
pharmaceutical industry: as our biomedical knowledge in-
creases we are simultaneously witnessing a decline in the 
number of new drugs being approved, combined with an 
economically unsustainable rise in costs. The year 2007 saw 
the number of new drugs approved for sale drop to 16 new 
molecular entities (NMEs), its lowest level since 1983 [6] 
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lating new data and knowledge into new therapies is the 
challenge at the heart of this paradox. New, more cost-
effective and efficient methods of drug discovery are ur-
gently required if we are to tackle the multiple global health 
challenges of emerging and neglected infectious diseases for 
which there is relatively little basic science investment. 
  The advent of high-throughput genome sequencing tech-
nology offers the possibility that the genome sequence of an 
emerging pathogen can quickly be determined soon after its 
identification. However our ability to exploit a pathogen’s 
genome information, with the goal of identifying potential 
therapies for testing, is still measured in the order of years, 
judging by the lack of progress in infectious disease thera-
pies derived from genetic analysis [8]. 
2. NEED FOR INFECTIOUS DISEASE INFORMAT-
ICS 
  The magnitude of the threat of the infectious diseases has 
resulted in recent calls for global efforts to counter the threat. 
In particular the application of informatics has been recog-
nised to aid generation, application and management of in-
formation and intellectual property to contribute to innova-
tion and promote public health [9-11]. The Sixty-First World 
Health Assembly’s report of the Intergovernmental Working 
Group on Public Health on a Global Strategy and Plan of 
Action on Public Health, Innovation and Intellectual Prop-
erty (WHA61.21) [9] section 35, 5.1 calls for:
36 (5.1) supporting information sharing and capacity build-
ing in the application and management of intellectual prop-
erty with respect to health related innovation and the promo-
tion of public health in developing countries. 
(c) facilitate widespread access to, and promote further de-
velopment of, including, if necessary, compiling, maintaining 
and updating, user-friendly global databases which contain 
public information on the administrative status of health-
related patents, including supporting the existing efforts for 
determining the patent status of health products, in order to 
strengthen national capacities for analysis of the information 
contained in those databases, and improve the quality of 
patents. 
  Furthermore, Rubin and co-workers at the University of 
Pennsylvania Institute for Strategic Threat Analysis and Re-
sponse have called for a ‘Comprehensive International Com-
pact for Infectious Diseases’ [10, 11] to ensure coordinated 
global research and development efforts are directed to en-
suring we have sufficient drugs and preparedness to tackle 
the present and emerging threat of infectious diseases. The 
objective of the Compact is to minimize the impact of infec-
tious diseases on national and international health, maximize 
social and economic development and enhance international 
security by creating a coordinated, global approach to the 
problems. In order to undertake this objective effectively, 
Rubin proposes the legal framework of a Compact to de-
velop a comprehensive agreement between governments 
powers, the scientific community, the private sector and 
other stakeholders that will limit and control known, newly 
discovered or deliberately created infectious diseases. The 
four missions of the Compact are 
1) Establish, maintain and monitor a shared international 
data and knowledge base for infectious diseases, includ-
ing but not limited to bio-surveillance information, rele-
vant pharmaceutical and basic research data and suites 
of services and skills. 
2) Establish, implement, maintain and monitor a network 
of international basic science research centers that will 
support fundamental investigations into the pathophysi-
ology of certain microbial threats to global health. 
3) Expand capabilities for the production of vaccines and 
therapeutics expressly for emerging and re-emerging in-
fections. 
4) Establish, implement, maintain and monitor interna-
tional standards for best laboratory and regulatory prac-
tices. 
  The infectious disease informatics strategy we discuss 
below is a response to both the aims of Mission I of the In-
ternational Compact for Infectious Diseases and the Section 
36:5.1(c) of the Sixty-first World Health Assembly’s resolu-
tion WHA61.21 on Global Strategy and Plan of Action on 
Public Health, Innovation and Intellectual Property to ensure 
the effective use of information to encourage innovation in 
discovery and development of new infective disease medi-
cines. 
3. DRUG DISCOVERY STRATEGIES 
  The multiple challenges of endemic, pandemic and epi-
demic neglected and emerging infectious diseases calls for a 
global, systematic approach to accelerating our current ef-
forts at discovery of pharmacological agents against these 
afflictions [9-12]. The rapid advances in genome sequence 
technology and informatics provide us the tools to devise a 
strategy to systematically exploit the wealth of information 
continuously being generated by the global biomedical en-
terprise for other purposes, and apply it to the search for new 
agents for infectious diseases. Thus the overall objective of 
this review is to illustrate the types of systems and general 
methodologies that could enable the rapid generation of 
plausible and testable medical hypotheses for pharmacologi-
cal experiments by uncovering as yet undiscovered and un-
explored relationships in the biomedical-related databases 
and literature corpus. In particular, our goal is to identify 
potential drug targets within pathogen genomes [13] and host 
genetic factors [14, 15] and prioritize which pharmacological 
experiments are most likely to rapidly discover drug-like 
lead compounds against a pathogen (i.e. which specific com-
pounds and drug targets should be screened, in which assays 
and where they can be sourced or undertaken). 
3.1. Rethinking Genome-Based Drug Discovery 
  The growing number of available genome sequences of 
human pathogen allows, for the first time, the rational priori-
tization of all potential drug targets for a wide range of 
emerging and neglected infectious diseases. The first genera-
tion of genome-based drug discovery projects have had rela-
tively little success, to date, especially in the field of anti-
bacterials [8,16]. The major drawback of earlier approaches 
was that despite significant upfront investment in under-
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fidence-in-rationale in the molecular target, there is a high 
risk that drug screening efforts will yield very little. Payne et
al. recently described the challenges of an industrial genome-
lead high throughput screening strategy to discover novel 
anti-bacterials [8]. Over 7 years GSK invested in the target 
validation of over 300 bacterial targets and showed 160 of 
them to be genetically essential. Seventy of the essential tar-
gets were screened against GSK’s corporate compound col-
lection in high throughout screens. The results were disap-
pointing. Only 16 of the 70 HTS run gave hits and only 5 
resulted in the discovery of lead compounds against (peptide 
deformylase (PDF), enoyl-acyl carrier protein reductase 
(FabI), 3-ketoacyl-acyl carrier protein III (FabH), methionyl 
tRNA synthetase (MetRS) and phenylalanyl-tRNA syn-
thetase (PheRS) targets). Following initial efforts in lead 
optimization only one lead series for PheRS were still being 
pursued at the time of publication. The unsustainable failure 
rate genome-lead anti-infective drug discovery calls for a re-
evaluation of the assumptions behind the strategy. 
3.1.1. Chemogenomics 
One of the key reasons for the failure of the first generation 
of anti-infective genomics-lead drug discovery campaigns 
was dominance of biological over chemical considerations at 
the target selection stage. Chemical considerations, such as 
tractability as a way of assessing a target’s ‘druggability’ and 
the diversity or appropriateness of the chemical space cov-
ered by compound libraries being screened against novel 
targets, are vital factors in improving the likelihood of suc-
cess of screening campaigns. The ‘druggability’ of a molecu-
lar target, such as a protein, is its inherent ability to be modu-
lated by a high affinity, ‘drug-like’ small molecule [17-21]. 
There are strong evolutionary arguments why proteins have 
evolved exquisite molecular recognition capabilities to avoid 
unwanted functional disruption in the vast sea of small 
molecule metabolites in which they exist. Current estimates, 
from analysis of the pharmaceutical industry screening data, 
suggest that only approximately 15% of proteins expressed 
by an organism’s genome have any inferred evidence of be-
ing potentially modulated by drug-like compounds [13, 17, 
22]. Additionally druggability is an attribute that is likely to 
be independent of lethality. Many genome-scale comprehen-
sive knock-out studies in model organisms have consistently 
identified around 19% of genes to be individually essential. 
Thus targets that are both lethal and druggable represent an 
intersect that is less than 3% of the proteins expressed in a 
genome (assuming lethality and druggability are not corre-
lated factors). When selectivity and the often required broad 
activity spectrum across many genomes is taken into account 
(as is the case with anti-bacterial target hunting) then even 
this small percentage of suitable proteins in a genome, de-
creases further still.
  Despite the fact that our knowledge of observed attrib-
utes of the vast majority of pathogen proteins is limited or 
missing, it is possible to develop methods to prioritize poten-
tial drug targets from a pathogen genome a priori by infer-
ence from the collective wealth of bio-pharmacology knowl-
edge available, such as genome sequences, model organism 
knock-outs, protein structures, medicinal chemistry struc-
ture-activity data and literature abstracts [13, 23-26]. The 
strategy of exploiting the wealth of knowledge of drug tar-
gets and associated compound properties is known as che-
mogenomics [27-30]. Proteins deemed to be potential drug 
targets would be those which are known or predicted to have 
a high probability of finding a drug-like chemical lead, and 
are known or are inferred to be essential to the pathogen for 
which selective drugs, non-toxic to humans could be devel-
oped. For example druggability can be assessed a priori
from protein sequence and protein structures using large-
scale, chemogenomics databases [17, 31] and protein struc-
ture binding site analysis [18, 19, 21]. In addition to the pub-
lished data on genes known to be essential for certain patho-
gens, lethality data of which genes are predicted to be essen-
tial can either be inferred from orthologues of large-scale 
model organism knock-out studies [13, 23, 32] or predicted 
by network analysis of metabolic or reconstructed biochemi-
cal networks [33-38]. Importantly essential genes do not 
have to be unique to a parasitic organism to be drug targets. 
Molecular differences in drug binding sites, identified 
through protein structure can be exploited by drug design to 
achieve selectivity and therapeutic index. For example, the 
clinically useful drug trimethoprim and its derivatives inhibit 
bacterial dihydrofolate reductase (DHFR) but not the related 
essential human enzyme. Selectivity between homologous 
human and parasite proteins can be calculated by analysis of 
the sequence of binding sites of protein models at genome-
scale [13, 39, 40]. Toxicity, or other undesired pharmacology 
that may result from binding to a host genome orthologue, 
can often be designed out. 
  Furthermore, not only is it important to prioritize poten-
tial drug targets based on a set of criteria and known and 
inferred attributes, also it is also necessary to identify poten-
tial pharmacological experiments to undertake - by providing 
details of specific compounds to test, assay protocols, as well 
as the names of relevant experts and materials, based on an 
objective analysis of all the available biomedical informa-
tion. The availability of pathogen genome data therefore 
provides the basis for developing methods to prioritize, a
priori, the potential drug target and pharmacological land-
scape of an infectious disease. This has not been the case 
until now. 
  Traditionally whole organism screening against specific 
compound collections has been the primary method of anti-
infective drug discovery. The principle drawback of screen-
ing chemically diverse libraries with no knowledge of spe-
cific protein is the ratio of the global in vivo screening capac-
ity to the total number of potentially available compounds. In 
contrast, chemogenomic-based drug discovery against spe-
cific targets is designed to test a large number of compounds 
in molecular biochemical or binding assays in order to triage 
down to a small number of compounds, with pre-selected 
drug-like properties, with known or predicted in vitro effec-
tiveness against specific targets. The most promising com-
pounds can then be tested in whole organism (in vitro) and in 
animal models (in vivo). Thus chemogenome-based strate-
gies enable a far greater number of compounds with a higher 
a priori probability of being active in vivo. This is especially 
important because there is a limited capacity for performing 
in vivo screening assays, which is a particularly acute prob-
lem in the area of the neglected parasitic diseases. There 
have been tentative developments to apply a chemogenomics 
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the TDR Targets Database, sponsored by the World Health 
Organisation Special Programme for Research and Training 
in Tropical Diseases (TDR) (http://TDRtargets.org), where a 
limited amount of druggability information has been calcu-
lated and disclosed for Mycobacterium tuberculosis (tuber-
culosis), Plasmodium falciparum (Malaria), Trypanosoma 
brucei (Human African Trypanosomisas), Trypanosoma 
cruzi (Chagas' disease) and Leishmania major (Leishmania-
sis) 
13. Genome-scale drug target prioritization strategies 
have also been applied by other groups to Mycobacterium 
tuberculosis [25], Brugia malayi (lymphatic filariasis) [23] 
and Schistosoma mansoni (schistosomiasis) [26]. However, a 
significant amount of further development is need to im-
prove the utility of the chemogenomics data and druggability 
prioritisation methods used in the first attempts at whole 
genome drug target rankings, not only for selected tropical 
disease pathogens but, potentially, for all human pathogens. 
The issue of prioritization of drug targets from pathogen 
genomes is vital if we wish to maximise the limited drug 
discovery resources available to neglected diseases, where 
the global drug discovery portfolio against some of the ne-
glected diseases may only be handful of credible screening 
projects.
3.1.2. Polypharmacology 
  A major aim of the first generation of genome-based drug 
discovery projects was to identify single gene prod-
ucts/proteins that are essential when deleted. This focus on 
single, essential proteins is limited for two reasons. First, the 
downstream difficulty and low inherent likelihood of discov-
ering small molecule leads has often only been considered 
after significant investment in biology (hence the argument 
for chemistry-led approaches, as discussed above). Secondly, 
if a drug is discovered, a single amino acid mutation is often 
enough to confer drug resistance. However, many effective 
antibiotics act by targeting multiple proteins simultaneously 
rather than individual proteins. In contrast to the ‘single tar-
get approach’, multi-drug combination therapies are the main 
strategy to reduce the development of drug resistance in 
many anti-infective regimes, such as current anti-HIV and 
anti-tuberculosis therapies. By attacking multiple, mutually 
exclusive drug binding sites in a pathogen’s genome the 
emergence of drug resistance can be delayed as the probabil-
ity of simultaneously developing multiple mutations, even in 
a single organism can be less than the pathogen population 
size multiplied by the rate of mutation. However, the ability 
of multi-drug combination therapies to delay the emergence 
of drug resistance is dependent on the continuous presence 
of optimal drug concentrations, which in turn is dependent 
on patient compliance, which can be challenging when a 
patient is faced with adhering to a cocktail of drugs with 
complex dosing schedules and varying pharmacokinetics. 
Reduction in the levels of just one drug can result in drug 
resistance emerging. Reviews of the modes-of-action of the 
current pharmacopeia of anti-bacterials reveals the majority 
of effective antibiotics act by targeting multiple proteins si-
multaneously rather than individual proteins [41-43]. By 
searching for single essential targets the first generation of 
genome-lead anti-bacterial drug discovery projects failed to 
rediscover many of the known antibiotic drug targets. For 
example, the anti-bacterial action of -lactams are dependent 
on the inhibition of at least two of the multiple penicillin-
binding proteins (PBPs) since multiple PBPs can be deleted 
with no effect on phenotype [44]. Similarly, fluoroquinolone 
antibiotics are dually targeted inhibiting the topoisomerase 
proteins ParC and GyrA 58 [45]. D-cycloserine acts on four 
targets, through inhibition of both pairs of alanine racemase 
and D-ala-D-ala ligase. Likewise, fosfomycin overcomes the 
redundancy of UDP-N-acetlyglucosamine enolpyruvyl trans-
ferases by inhibiting them both. This feature of multiple 
genes coding for a core biological function can be seen in the 
context of the evolution of a ‘robust system’, relatively im-
mune to external influence and control – precisely what is 
required for a pathogen to co-exist with hosts capable of 
mounting a response to infection. 
  Systematic experiments with dual knock-outs in model 
systems have shown that, whilst the deletion of two genes in 
isolation may show no effect, the simultaneous deletion of 
two genes can lead to ‘synthetic lethality’ or ‘synthetic sick-
ness’. Therefore if we wish to design single drugs that limit 
drug resistance we could consider the development of meth-
ods to identify and prioritize combinations of targets that can 
be inhibited by the same compound and are either all essen-
tial individually or in combination (i.e.,synthetic lethality) 
[41, 42, 46]. Based on the examples above, common func-
tions encoded by paralogous genes is one such simple priori-
tisation strategy. By targeting two or more essential genes 
with a single chemical agent, the ability to delay drug resis-
tance is designed into the target discovery strategy from the 
start. Given the failure of current genome-based strategies 
for discovering new antibacterial drugs, learning the lessons 
of the previous successful generation of antibacterial drugs 
may encourage the development of anti-infective drug dis-
covery strategies with an inherently greater chance at delay-
ing the emergence of drug resistance. A strategy of poly-
pharmacology – compounds that act via multiple proteins – 
may therefore increase the opportunity space by increasing 
the number of essential target systems [47] and delaying the 
emergence of drug resistance [42, 48]. The polypharmcology 
strategy can also be applied to the design of single drugs that 
could limit the evolution of drug resistance, if we developed 
methods to search and prioritize which combinations of tar-
gets can be inhibited by the same drug and are both indi-
vidually essential. Thus we are both expanding the range of 
proteins we may consider and prioritize as drug targets but 
also pragmatically focusing on exploiting the wealth of cur-
rent chemical and pharmacology information. 
  Informatics methods for assessing selectivity have also a 
complementary application in the prediction of polypharma-
cology. In order to devise methods to predict polypharma-
cology it is useful to classify different types of polypharma-
cology behaviours. Therefore we propose classifying poly-
pharmacology into three classes to assist algorithm devel-
opment. 
3.1.2.1. Type I Polypharmacology
  Refers to the binding of a compound to related homolo-
gous targets. The promiscuous binding of many inhibitors 
between related protein kinases is an example of this type of 
polypharmacology. Structure-based binding site se-
quence/structure alignments are therefore a useful tool for 
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3.1.2.2. Type II Polypharmacology
  Refers to a compound binding to proteins that are non-
homologous at the sequence level but share a common en-
dogenous substrate or ligand. Metabolic and pathway data-
bases are useful data sources for identifying potential candi-
dates for Type II polypharmacology. 
3.1.2.3. Type III Polypharmacology
  Refers to the binding of a compound to targets that are 
non-homologous at the sequence nor share common endoge-
nous substrate or ligand. There may indeed exist unexpected 
commonalities in the topology of physico-chemical charac-
teristics of two apparently unrelated binding sites by chance. 
Several chemoinformatics methods of assessing chemical 
structure similarity show promise in prediction of Type III 
Polypharmacology between unexpected targets [31, 49]. 
3.1.3. Identifying Broad Spectrum Targets 
  In addition to the polypharmacology behaviour of agents 
against multiple proteins within a pathogen one can also 
consider polypharmacology of agents between organisms. A 
compound that is predicted and observed to bind to essential 
targets across a number of pathogens, yet be selective against 
a human orthologue may have the potential to be developed 
into a drug with a broad anti-parasitic spectrum to reduce the 
burden of patients suffering from multiple infections, in par-
ticular the common experience of poly-parasitism in the de-
veloping world [50]. Although the chances of such discover-
ies may be small, initiating systematic search methods for 
polypharmacology opportunities across multiple genomes 
may identify several such opportunities. Large-scale com-
parative chemogenomics can systematically identify cross-
species opportunities for anti-infective drug discovery by 
mapping the landscape of all putative drug targets, providing 
a common framework on which to focus the global efforts in 
tropical disease research. Therefore comparative chemoge-
nomics and essentiality analyses across a large number of 
pathogen genomes can provide valuable information, espe-
cially in identifying common drug targets between patho-
gens, specifically searching for drugs against poly-parasitism 
or identifying the closest pathogen proteins most likely to 
bind a specific set of compounds. 
3.2. Indications Discovery: Reprofiling of Drugs and 
Targets 
  In contrast to phenotypic-based screening or genomics-
led approaches to drug discovery there are emerging discov-
ery strategies that may be beneficial to anti-infectives drug 
discovery. One such strategy is indication discovery [51], 
also known as drug reprofiling or drug repurposing [52, 53]. 
The history of medicine is replete with examples of seren-
dipity: compounds, which were originally developed for one 
disease being subsequently found to be beneficial against 
another disorder. Far from being rare, the number of thera-
pies being marketed for new indications per annum is rising 
and about equal to the number of new therapies arising from 
new compounds with novel mechanisms of action reaching 
the market each year [54] . One of the most famous exam-
ples of serendipity in medicine is Alexander Fleming’s dis-
covery of penicillin. However, the history of penicillin also 
contains another lesson for drug discovery: buried in the 
scientific literature are several independent experiments on 
the anti-bacterial effects of Penicillium [55]: Billroth in the 
1860s by Lister, Tyndall, Roberts, Pasteur and Joubert in the 
1870s and by Duchesne in 1886 and by Twight and Gratia 
and Dath in the 1920s. The examples of the repeated discov-
ery of penicillin illustrate what Swanson calls ‘undiscovered 
public knowledge’ [56]. Indeed, protein targets as well as 
compounds may find alternative medical utility from their 
primary disease association [51, 57]. Ironically, the sheer 
wealth of biomedical information may itself be an impedi-
ment to progress. The exponential growth of published bio-
medical knowledge creates the paradox where the individual 
scientist or clinician knows a diminishing fraction of all 
knowledge in the field. The drawback of search engines such 
as Pubmed or Google Scholar is that they only allow one to 
find what one is searching for, whereas the lesson of seren-
dipity in science is that a development in any one field may 
be of value in generating novel hypothesis in another, appar-
ently unrelated field [58]. Thus serendipity could be mim-
icked by developing systems that mine the mass of appar-
ently unconnected biomedical information to propose and 
score new medical hypotheses for new treatments for unmet 
medical needs [57]. 
  Given the rapid rise of new knowledge, information sys-
tems that automatically search for associations between pro-
teins, compounds and diseases could have immense impact 
in the biomedical sciences, in particular as a cost effective 
method of discovering pharmacological agents against ne-
glected and emerging infectious diseases. In the field of anti-
infectives there is a growing record of parasite drug targets 
that are orthologues of human drug targets. For example, 
cholesterol biosynthesis inhibitors of human squalene syn-
thase have been demonstrated to block Staphylococcus 
aureus virulence by the inhibition of the structural homolog 
S.aureus dehydrosqualene synthase [59]. Likewise the 
chemical inhibitors of the Plasmodium falciparum
orthologues of the human anti-cancer target methionine 
aminopeptidase 1b possess antimalarial activity [60, 61]. The 
folate pathway has proved a rich target for drug treatment 
not only for anti-cancer and rheumatoid arthritis but also for 
several parasites include P. falciparum and the T. brucei.
The advantage of finding new uses for existing compounds 
and drug targets is the significant saving in both cost and 
time compared to the de novo discovery and development of 
a new chemical or biological entity, acting via an unprece-
dented drug target. 
4. DISCOVERY INFORMATICS FRAMEWORK 
In order to systematically map out the potential pharmacol-
ogical landscape for a pathogen a framework is required that 
can guide the development of informatics services that 
would enable the range of diverse drug discovery strategies 
outlined above. If our goal is to systematically infer the at-
tributes of pathogen proteins relevant to drug hunting and 
prioritize those attributes by practical considerations of drug 
discovery then we propose the required informatics infra-
structure will need to contain three main overlapping areas: 
1) Druggability 
2) Selectivity  
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  Ultimately a potential pathogenic drug target is identified 
by its attributes describing the likelihood of discovering 
small molecule modulators and in the confidence we assign 
to the prediction of those attributes. 
4.1. Druggability 
  The ‘druggability’ of a target encompasses the chemical 
space associated with a protein, which in turn is determined 
by the physico-chemistry and molecular architecture of the 
binding sites of interaction [17-19, 21]. A number of investi-
gators have used the physico-chemical basis of molecular 
interactions to predict druggability based on protein struc-
tures [18, 19, 21, 62-64]. Since exact structural information 
is not known for the vast majority of pathogen proteins, se-
quence based similarity methods can be applied to identify 
pathogen proteins that are homologous to proteins that are 
known to bind small molecule, drug-like ligands found in the 
chemogenomics database such as ChEMBL 
(www.ebi.ac.uk/chembl). However, the limitations of infer-
ring druggability by solely sequence-based methods include 
the observation that many druggable protein families may 
share little overall sequence similarity yet still maintain a 
common druggable binding site, and that the drug binding 
site may be composed of elements from several constituent 
proteins in a complex, with each component needing to be 
present for the binding site to exist. Moreover many drug 
targets have multiple ligand binding sites, which in turn can 
have different modes of action (e.g. substrate competitive, 
allosteric) and that each of these binding sites exhibit differ-
ent degrees of druggability and bind ligands from different 
areas of chemical space. Drug binding sites are far more di-
verse than defined enzymatic active sites within single pro-
tein domain. Indeed several known drug-binding sites occur 
at the interfaces between domains and protein complexes. 
The creation of the binding site itself may also be a temporal 
process that depends upon post-translational modification, 
induced fit or an allosteric cooperativity between other 
events in the protein complex. Thus one approach to infer-
ring druggability across a highly diverse sequence space is to 
construct an ontology that defines the molecular interactions 
between components of binding sites and then use this on-
tology as a platform for sequence based analysis. However, 
our goal is not only to identify which pathogen or host pro-
teins are likely to be druggable but also to identify specific 
compounds and areas of chemical space which have the 
highest likelihood of being active against the putative drug 
targets of interest. Prioritized compounds can then be sour-
ced from commercial or proprietary compound collections 
for screening in appropriate assays. 
  Until recently the vast amount of pharmacological data 
linking chemical structures to biological activities have not 
been available in computationally accessible formats. The 
vast majority of biological activity data on chemical struc-
tures resides within the informatics systems of the large 
pharmaceutical companies. Whilst a fraction of the more 
useful screening data in these sources has previously been 
publicly disclosed in the form of patents or (less often) in 
journal articles, the information is not easily accessible for 
large-scale machine learning. In order to mine the wealth of 
biologically-active chemical information that is present in 
patents and medicinal chemistry journals, the information 
needs to be extracted, standardized, normalised and cross-
validated. Recently our ability to access and mine these data, 
outside of the pharmaceutical industry, has improved consid-
erably. Firstly, the National Institutes of Health (NIH) 
Roadmap initiative has lead to the public deposition of large 
amounts of novel screening information, from the NIH Mo-
lecular Libraries and Screening Centers Program in the Pub-
Chem repository. Secondly, the Wellcome Trust has made a 
major £4.7 million investment at the EMBL European Bioin-
formatics Institute (EMBL-EBI, Cambridge UK) to place a 
large amount of curated medicinal chemistry data in the pub-
lic domain, in the form of the ChEMBL databases. The
ChEMBL database of chemical structure-activity relation-
ship information comprises of data extract from the medici-
nal chemistry literature since 1980. This database represents 
a comprehensively annotated chemogenomics resource of 
approximately 450,000 synthetically tractable bioactive com-
pounds and covering around 5,700 curated targets which 
have been abstracted from over 26,000 articles from the pri-
mary literature, most notably Journal of Medicinal Chemis-
try (1980-2009) and Bioorganic Medicinal Chemistry Letters
(1990-2009). These two journal contain 90% of the pub-
lished medicinal chemistry structure-activity data according 
to a recent study by AstraZeneca (P. Leeson, pers. comm.) 
The ChEMBL databases also contain a curated set of ap-
proved drugs and their targets, with enhanced and comple-
mentary annotation compared to other public resources such 
as Drugbank [65]. These databases provides an essential data 
source for inferring small molecule druggability for patho-
gen proteins. Thirdly, advances in text mining have enabled 
the development of chemical name recognition software that 
can be used to extract chemical names from the vast amount 
of patent information that exists globally. IBM, for example, 
in collaboration with a number of pharmaceutical companies, 
have trained a chemical extraction engine to recognise the 
nuances and common errors that often occur in the text of 
patents and patent applications and have used this technol-
ogy to extract over 12 million unique chemical structures 
from the patent corpus of over 12 million patent documents 
and over 18 million Medline abstracts, titles and annotations. 
Using IBM’s Blue Gene computer this database of chemical 
structures extracted from patents can be updated daily. Rou-
tinely the system annotates over 100,000 documents per 
month but is capable of annotating around 1 billion pages in 
approximately 3 hours, if necessary. This wealth of chemical 
data, that can now be linked to biological activity with vary-
ing degrees of confidence, provides the basis for considering 
that it may now be possible to link suitable and accessible 
chemistry to pathogen drug targets in a systematic and 
timely fashion using a range of virtual screening tools, in-
cluding: 1-dimensionals fingerprint based similarity tools 
such as Bayesian activity modelling [31, 66-68] and Similar-
ity Ensemble Approach [49, 69]; 2-dimensional graph-based 
and pharmacophore matching tools [70, 71]; and 3-
dimensional structure-based docking tools, where protein 
structural data is available (from direct x-ray crystal struc-
tural data or inferred via comparative modelling) [72]. 
4.2. Selectivity 
  A second key attribute to identifying and prioritizing 
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between the parasite and the host. Conventionally, the per-
ceived requirement for absolute selectivity over host func-
tionality has typically led to the strategy of selectively 
searching for pathogen targets that are not present in the 
host. The absence of an orthologue from the host of a patho-
gen drug target is a valid assumption, but it does rule out 
many core essential genes that are common between diverse 
species. However, selectivity between a drug target that is 
common between the host and pathogen can still be obtained 
by (i) exploiting amino acid differences in the binding site 
(binding site selectivity), or (ii) by selecting compounds 
which exhibit different kinetic off-rates between the host and 
pathogen target (kinetic selectivity) or (iii) by a difference in 
biological importance of the target to each organism (bio-
logical selectivity) or (iv) by designing (or discovering) a 
compound that is differentially metabolised from a prodrug 
or into a inactive metabolite between host and pathogen 
(metabolic selectivity) or (v) by differences in transport and 
excretion (for example, active uptake). An important aid in 
understanding binding site selectivity in particular is com-
parative modelling and binding site sequence alignments. 
Sali’s group at UCSF has developed a proteome scale mod-
elling workflow that has been applied to a number of human 
pathogen genomes [40]. The output models have been made 
available to both the TDR Targets database [13] and the 
Tropical Disease Initiative’s kernel [39, 73]. 
4.3. Efficacy 
  The third key attribute necessary to prioritize a pathogen 
drug target is its relevance or functional linkage to the con-
trol of the disease pathology, or what we shall call its ‘effi-
cacy’: the biological quality of the drug target. We define a 
target’s efficacy as the effect its modulation has on the infec-
tious disease state. In short, it is an estimate of the capacity 
for a compound binding to a target to decrease the scale or 
severity of the infection. Whilst the concepts of druggability 
and selectivity are ultimately physico-chemically based, the 
concept of ‘efficacy’ is context-based, dependent on the ho-
listic functioning of the host-pathogen system. The contin-
uum of efficacy stretches across essential genes, syntheti-
cally lethal gene combinations, virulence factors and other 
host factors. To achieve the desired lethal or static effect 
different degrees of inhibition may be required. For example, 
genetic knockouts result in the complete ablation of both the 
enzymatic and structural functions of a protein. If the essen-
tial properties of the protein is due to it structural role, no 
enzyme active site inhibitor, no matter how potent, can 
mimic that deletion. The exact mimicking of a genetic 
knockout by a chemical may be practically impossible. To 
achieve the required functional suppression an irreversible 
covalent inhibitor, or very slow inhibitor k(off) kinetics may 
be required to provide insurmountable inhibition [74, 75]. 
The issue of insurmountable inhibition maybe particularly 
important if the target is extracellular where mass action 
effects are unfavourable as the ligand may diffuse off, if 
there is a high concentration of competing substrate or if a 
high level of inhibition is required to perturb the organism 
[42]. Predicting the effects of a partial degree of perturbation 
or even complete deletion, of a particular protein on a patho-
gen-host disease state is one of the most difficult scientific 
challenge facing the infectious disease community. However 
there are a growing number of experimental and computa-
tional methods than can be employed to tackle this chal-
lenge. In addition to published data on genes known to be 
essential that exist for some pathogens, lethality data of 
which genes are predicted to be essential can either be in-
ferred from orthologues of large-scale model organism 
knock-out studies [13, 23, 32] or predicted by network 
analysis of metabolic or reconstructed biochemical networks 
[33-38]. One hypothesis that appears correlated with the le-
thality of single gene deletions and synthetic lethality of 
double knock-outs is a topological one - the ‘missing alterna-
tive’ in metabolic networks [76, 77]. Essentiality and syn-
thetic lethality can be considered as emergent properties that 
result from biochemical network wiring and dynamic rewir-
ing. The ‘missing alternative’ hypothesis suggests syntheti-
cally lethal genes function in parallel or in compensating 
pathways.  
  In addition to the large-scale knock out studies in patho-
gen genomes, genome-wide RNA interference is increas-
ingly being used to identify host factors critical for pathogen 
infection, such as HIV-1 [14], the flavivruses [78], West Nile 
virus [15] and Dengue virus [79]. The discovery of leads 
against human host factors also benefits from the systematic 
chemogenomics analyses outlined above. Indeed, the recent 
approval of maraviroc [80], a potent, selective drug targeting 
the human CCR5 chemokine receptor, a major co-receptor 
for HIV-1, illustrates the value of targeting essential host 
factors. 
5. CONCLUSIONS 
  A survey of the global pharmacology space reveals that 
with our current chemogenomics sources we can identify 
drug-like chemical leads for ca 1500 protein targets [31]. 
Using a variety of established and developmental chemoin-
formatics and bioinformatics techniques we can potentially 
link the known biologically active chemical space to a wider 
range of proteins to identify putative and focussed sets of 
compounds for screening. The informatics strategy outlined 
here holds the promise of making significant impact on in-
fectious disease drug discovery and bio-defence strategies 
against emerging pathogens. The information-based strategy 
is global, systematic and scalable and can potentially be ap-
plied to analyze the genomes of protozoa, helminths, fungi, 
bacteria and viruses. The strategy we have outlined is de-
signed to rationally identify targets with a high chance of 
finding a good chemical starting point, from which selective 
drugs, that are non-toxic to humans, could be developed, and 
also extends the range of current targets for consideration to 
include synthetically lethal and polypharmacology targets. 
The scalability of the strategy and the increasingly ‘open’ 
nature of scientific data indicates that its chance of success 
increases as it is applied to a wider range of pathogens and 
integrates data from a wider range of information sources. 
  The strategy outlined here could greatly enable the cross-
fertilization of ideas between independent groups and across 
geography. A number of collaborations could be spurred by 
alerting scientists who are working on specific compounds or 
protein in one area that their research could be beneficial to 
another group working on an infectious disease, elsewhere. 
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between genomes, compounds, assays and drug targets the 
limited resources available to neglected and emerging dis-
eases could be expanded as they would benefit from the 
greater, global biomedical enterprise by enabling the deliber-
ate re-use of knowledge and provide greater returns on fund-
ing agency investments. 
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